10/14/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – mifepriston

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
3 3
3 3

Mifepriston

Mifepriston

Klass : 3

Visa all info

Skriv ut

Kontakta oss

  1. Exelgyn. Mifegyne Produktresumé. Läkemedelsverket [www]. [updated 2024-07-08, cited 2025-09-16].

  2. Bernard N, Elefant E, Carlier P, Tebacher M, Barjhoux CE, Bos-Thompson MA et al. Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study. BJOG. 2013;120(5):568-74.

  3. Sitruk-Ware R, Davey A, Sakiz E. Fetal malformation and failed medical termination of pregnancy. Lancet. 1998;352:323.

  4. Jingran G, Yan D, Xiaoying Y. Risk of teratogenicity in continued pregnancy after gestational exposure to mifepristone and/or misoprostol: a systematic review and meta-analysis. Arch Gynecol Obstet. 2024;310(3):1331-1342.

  5. UK Teratology Information Service (UKTIS). Exposure to mifepristone in pregnancy October 2022 Version: 4 . UKTIS [www]. [cited 2025-09-16].

  6. Reprotox. Mifepristone. Micromedex [www]. Micromedex. [cited 2025-09-08].

  7. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.

  8. Danielsson B, Vargesson N, Danielsson C. Teratogenicity and Reactive Oxygen Species after transient embryonic hypoxia: Experimental and clinical evidence with focus on drugs causing failed abortion in humans. Reprod Toxicol. 2023;122:108488.

  1. Exelgyn. Mifegyne Produktresumé. Läkemedelsverket [www]. [updated 2024-07-08, cited 2025-09-16].
  2. Bernard N, Elefant E, Carlier P, Tebacher M, Barjhoux CE, Bos-Thompson MA et al. Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study. BJOG. 2013;120(5):568-74.
  3. Sitruk-Ware R, Davey A, Sakiz E. Fetal malformation and failed medical termination of pregnancy. Lancet. 1998;352:323.
  4. Jingran G, Yan D, Xiaoying Y. Risk of teratogenicity in continued pregnancy after gestational exposure to mifepristone and/or misoprostol: a systematic review and meta-analysis. Arch Gynecol Obstet. 2024;310(3):1331-1342.
  5. UK Teratology Information Service (UKTIS). Exposure to mifepristone in pregnancy October 2022 Version: 4 . UKTIS [www]. [cited 2025-09-16].
  6. Reprotox. Mifepristone. Micromedex [www]. Micromedex. [cited 2025-09-08].
  7. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.
  8. Danielsson B, Vargesson N, Danielsson C. Teratogenicity and Reactive Oxygen Species after transient embryonic hypoxia: Experimental and clinical evidence with focus on drugs causing failed abortion in humans. Reprod Toxicol. 2023;122:108488.